863288-34-0
CJC-1295 (no DAC)
Tetra-substituted GHRH(1-29) analogue without the drug affinity complex. Short-acting.
Typical release99.0%
From
£42.00
In stock
Growth Factor & Secretagogue
HGH Fragment 176-191
hGH frag 176-191 · Growth hormone fragment 176-191
Unmodified C-terminal growth hormone fragment used in lipolysis research.
Total, ex VAT
£39.00
- Released at ≥ 98.0% (RP-HPLC, area %)
- Identity confirmed by ESI-MS against theoretical mass
- Batch certificate matched to the vial, verifiable online
- Same working day dispatch before 14:00, tracked
For laboratory research use only. Not for human or veterinary use, and not a medicine, food or cosmetic. Sold to qualified researchers and institutions who accept responsibility for safe handling and lawful use.
Compound data
What is in the vial
Indicative values for this line. The certificate issued with your batch is the authoritative record and reports the measured figures for the material you receive.
- CAS number
- 66004-57-7
- Molecular formula
- C78H123N23O23S2
- Average mass
- 1817.1 g/mol
- Residues
- 16
- Class
- Growth hormone C-terminal fragment
- Form as supplied
- Lyophilised powder
- Appearance
- White to off-white lyophilised powder
- Purity specification
- ≥ 98.0% (RP-HPLC, area %)
- Solubility
- Soluble in sterile or bacteriostatic water.
- Storage
- Lyophilised: −20 °C, desiccated and dark. Reconstituted: 2–8 °C.
Targets and pathways
- Lipolytic pathways downstream of the hGH C-terminal domain
Overview
About HGH Fragment 176-191
This is residues 176 to 191 of human growth hormone, unmodified. The fragment retains the lipolytic activity of the parent hormone while lacking its growth-promoting and insulin-antagonising activity, which is the observation that made the C-terminal region interesting in the first place.
It is held alongside AOD-9604, which is the same region with an added N-terminal tyrosine. Comparing the two is how the effect of that modification is assessed, and it also guards against the frequent confusion between them in secondary sources — the two are routinely quoted under each other's names.
In short
- Unmodified hGH(176-191) with free termini
- Distinct from AOD-9604, which carries an added N-terminal tyrosine
- Retains lipolytic activity without growth-promoting activity
- Released at ≥ 98.0% area-percent by RP-HPLC
Where it is used
Research applications
Lipolysis
Used in adipocyte preparations to study fat mobilisation independent of the somatotropic effects of full-length hGH.
Functional dissection of hGH
Demonstrates that distinct activities of the hormone map onto distinct regions of the sequence.
Analogue comparison
Held against AOD-9604 to assess what the tyrosine modification changes.
Handling
Reconstitution and stability
Reconstitution
Reconstitute with sterile or bacteriostatic water added slowly against the inner wall of the vial. Allow the cake to dissolve without agitation, swirling gently if required. Do not vortex or shake.
Stability
Lyophilised at −20 °C, desiccated and protected from light, stable for at least 24 months. Reconstituted and held at 2–8 °C, use within 28 days. Avoid repeated freeze-thaw.
Notes
- Bring the vial to room temperature before opening so atmospheric moisture does not condense onto cold powder.
- Record the reconstitution date on the vial; concentration drift between runs is usually evaporation, not synthesis variance.
- Aliquot at first reconstitution where the working programme needs more than a few withdrawals.
Laboratory reference
Reconstitution calculator
Enter the fill weight on the vial and the diluent volume you intend to add. The calculator returns the resulting solution concentration and the volume that contains a given mass.
- Concentration
- 2.500 mg/mL · 2500 µg/mL
- Volume containing target mass
- 100.0 µL · 0.1000 mL
Figures are mass-to-volume arithmetic for laboratory preparation of HGH Fragment 176-191 and take no account of net peptide content, which is stated on the batch certificate and should be applied to the fill weight before calculating. Nothing here constitutes dosing, administration or clinical guidance of any kind.
Published work
What the literature reports
Summaries of published findings, provided as research reference. These describe work done by others in preclinical and clinical settings; they are not claims about this material or outcomes for any reader.
Fragment lipolytic activity
Demonstration that the C-terminal region of hGH carries lipolytic activity separable from growth promotion.
Ng & Bornstein, Diabetes, 1978
Structure–function mapping
Work assigning distinct hGH activities to distinct sequence regions.
Reviewed in Wu et al., Hormone Research
Questions
HGH Fragment 176-191 — asked and answered
Something not covered here? Ask us directly — technical questions reach someone who runs the assays.
- Is this the same as AOD-9604?
- No. AOD-9604 is 177-191 with an added N-terminal tyrosine. This is 176-191 unmodified. Different masses, different retention times, frequently confused in secondary sources.
- Does it contain cysteine?
- Yes, and the fragment can form disulfide-linked dimer on ageing. This is reported on the certificate where detected.
- What is the solution shelf life?
- 28 days at 2–8 °C, though dimer formation is the limiting factor rather than hydrolysis.
Same class
Others in Growth Factor & Secretagogue
170851-70-4
Most orderedIpamorelin
Selective ghrelin receptor agonist pentapeptide with minimal cross-activity.
Typical release99.2%From
£34.00
In stock
86168-78-7
Sermorelin
The native GHRH(1-29) fragment, unmodified. The reference sequence for GHRH analogue work.
Typical release98.8%From
£52.00
In stock
218949-48-5
Tesamorelin
Full-length GHRH(1-44) with an N-terminal hexenoyl group for protease resistance.
Typical release98.6%From
£114.00
In stock
Important
HGH Fragment 176-191 is supplied strictly for laboratory research and analytical use. It is not a medicine, food, cosmetic or veterinary product; it is not for human or animal consumption; and it is not intended to diagnose, treat, cure or prevent any condition. It is not manufactured, tested or released to any standard that would support administration to humans or animals. Information on this page is compiled for research reference and is not medical advice. No dosing, administration or therapeutic guidance is given or implied. By ordering you confirm you are a qualified researcher or institution and accept responsibility for safe handling and lawful use.